Repligen Corp reports results for the quarter ended March 31 - Earnings Summary

• Repligen Corp RGEN.OQ reported quarterly adjusted earnings of 39 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 28 cents. The mean expectation of nineteen analysts for the quarter was for earnings of 35 cents per share. Wall Street expected results to range from 28 cents to 38 cents per share.

• Revenue rose 11.8% to $169.17 million from a year ago; analysts expected $163.83 million.

• Repligen Corp's reported EPS for the quarter was 10 cents​.

• The company reported quarterly net income of $5.83 million.

• Repligen Corp shares had risen by 12.9% this quarter and lost 0.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Repligen Corp is $194.00

This summary was machine generated from LSEG data April 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)